Skip to main content
logo
Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
86.63
-2.26 (-2.54%)
At close: Jul 2, 2026, 4:00 PM EDT
84.95
-1.68 (-1.94%)
After-hours: Jul 2, 2026, 6:58 PM EDT

Spyre Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-179.44-155.2-208.02-338.79-83.82-65.8
Depreciation & Amortization
---0.741.571.58
Stock-Based Compensation
41.5637.6144.8325.687.118.04
Other Adjustments
-40.55-45.7310.31217.670.50.64
Change in Receivables
---0.380.44-0.82
Changes in Accounts Payable
-0.57.65-16.21-2.18-2.641.07
Changes in Accrued Expenses
8.89-0.7614.61-4.89-0.84-0.37
Changes in Unearned Revenue
---0.58-0.883.58
Changes in Other Operating Activities
-13.51-12.82-2.930.92-1.58-1.62
Operating Cash Flow
-185.63-169.25-157.41-99.91-80.14-53.72
Capital Expenditures
-----0.04-0.57
Sale of Property, Plant & Equipment
---0.48--
Proceeds from Sale of Intangible Assets
377-15--
Purchases of Investments
-531.94-522.21-599.25-166.8-39.5-133.08
Proceeds from Sale of Investments
408.1371.74245.9739.996.55111.03
Other Investing Activities
---3.04--
Investing Cash Flow
-86.83-143.48-353.29-108.3957.01-22.62
Issuance of Common Stock
5.65314.44243.8984.9643.11.9
Net Common Stock Issued (Repurchased)
5.65314.44243.8984.9643.11.9
Issuance of Preferred Stock
--168.85281.92--
Net Preferred Stock Issued (Repurchased)
--168.85281.92--
Other Financing Activities
-0.3-5.41-1.84-5.8-0.42-0.51
Financing Cash Flow
321.16309.03410.91361.0842.681.39
Effect of Exchange Rate Changes on Cash and Cash Equivalents
---00.03-0.11-0.02
Net Cash Flow
11.64-3.7-99.79152.819.44-74.96
Free Cash Flow
-185.63-169.25-157.41-99.91-80.18-54.29
Free Cash Flow Per Share
-2.15-2.64-3.35-14.49-23.78-20.64
Levered Free Cash Flow
-184.56-161.14-212.55-343.63-88.23-62.15
Unlevered Free Cash Flow
-206.76-215.52-213.05-247.16-89.33-61.86
SEC Filings: 10-K · 10-Q